Advertisement

Annals of Hematology

, Volume 94, Supplement 2, pp 167–176 | Cite as

Managing pregnancy in chronic myeloid leukaemia

  • Renuka Palani
  • Dragana Milojkovic
  • Jane F. Apperley
Review Article

Abstract

Over the past decade, we have witnessed significant advances in knowledge of the biology and treatment of chronic myeloid leukaemia (CML). The development of molecular-targeted therapy with tyrosine kinase inhibitors (TKIs) has fundamentally changed the outcome of this disease. Treatment with TKIs is now the standard of care in patients with CML and has dramatically improved long-term survival in the majority of patients. Patients who achieve major molecular response (MMR) after 2 years of treatment with imatinib have survival rates comparable to those of the general population. The success of TKIs has led to durable molecular response and possibility of normal life expectancies, such that it is now timely to address quality of life aspects such as fertility, pregnancy and family planning. Pregnancy in CML presents specific management and therapeutic challenges for the patient and the physician. Despite the recent treatment advances, we still have limited data on the safety of TKIs in pregnancy and its effect on fertility. However, there is a cause for concern and heightened awareness following the occurrence of a constellation of rare congenital malformations and spontaneous abortions in association with imatinib therapy. When a patient becomes pregnant whilst receiving TKI therapy, the difficulty lies in balancing the risk to the foetus of continuing therapy versus the risk to the patient of treatment interruption and potentially losing optimal disease response. All couples should be counselled on the risks associated with pregnancy whilst receiving TKI therapy. This is an essential aspect in patient care and frequently not emphasized enough by physicians. At the time of diagnosis, fertility preservation should be discussed with both male and female patients of childbearing potential. They should be made aware of fertility options which are available such as semen cryopreservation, ovarian or oocyte retrieval and storage and embryo cryopreservation in view of the potential detrimental effect of TKIs on fertility and gonadal function. The recommendation given to patients planning pregnancy differs according to their disease response to TKI therapy, which is the most important prognostic factor in CML.

Keywords

Fertility Pregnancy Chronic myeloid leukaemia Tyrosine kinase inhibitors 

Notes

Acknowledgments

RP, DM and JFA are grateful to the National Institute of Health Research (NIHR) and the NIHR Biomedical Research Centre for the financial support.

Author contributions

RP, DM and JFA performed the literature review and wrote the manuscript.

Conflict of interest

Authors declare no conflict of interest with regard to this paper.

References

  1. 1.
    Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P (2010) Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029–1035CrossRefPubMedGoogle Scholar
  2. 2.
    Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122(4):515–522CrossRefPubMedGoogle Scholar
  3. 3.
    (2014) Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals CorporationGoogle Scholar
  4. 4.
    (2014) Sprycel (dasatinib): prescribing information. Princeton, NJ: Bristol-Myers Squibb CompanyGoogle Scholar
  5. 5.
    (2014) Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals CorporationGoogle Scholar
  6. 6.
    He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ (2008) Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metabol Dispos 26(12):2564–2570CrossRefGoogle Scholar
  7. 7.
    (2013) Bosulif (bosutinib) [prescribing information]. New York, NY: Pfizer IncGoogle Scholar
  8. 8.
    (2014) Inclusig (ponatinib) [prescribing information]. Cambridge, MA: Ariad Pharmaceuticals, IncGoogle Scholar
  9. 9.
    Ault P, Kantarjian H, O’Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J (2006) Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24:1204–1208CrossRefPubMedGoogle Scholar
  10. 10.
    Hensley ML, Ford JM (2003) Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 40(2suppl3):21–25CrossRefPubMedGoogle Scholar
  11. 11.
    Breccia M, Cannella L, Montefusco E, Frustaci A, Pacilli M, Alimena G (2008) Male patients with chronic myeloid leukemia treated with Imatinib involved in healthy pregnancies: report of five cases. Leuk Res 32(3):519–520CrossRefPubMedGoogle Scholar
  12. 12.
    Ramasamy K, Hayden J, Lim Z, Mufti GJ, Ho AY (2007) Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 137(4):374–375CrossRefPubMedGoogle Scholar
  13. 13.
    Iqbal J, Ali Z, Khan AU, Aziz Z (2014) Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. Leuk LymphomaGoogle Scholar
  14. 14.
    Zhou L, You JH, Wu W, Li JM, Shen ZX, Wang AH (2013) Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leuk Res 37(10):1216–1221CrossRefPubMedGoogle Scholar
  15. 15.
    Cortes J, O’Brien S, Ault P, Borthakur G, Jabbour E, Bradley-Garelik B, Debreczeni K, Yang D, Liu D, Kantarjian H (2008) Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood 112(11). Abstract 3230: Poster presented at: the 50th American Society of Hematology (ASH) Annual Meeting; December 6–9, 2008; San Francisco, USAGoogle Scholar
  16. 16.
    Gentile M, Guido M, Lucia E, Vigna E, Mazzone C, Recchia AG, Morabito F (2014) Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib. Leuk Lymphoma 55(3):709–710CrossRefPubMedGoogle Scholar
  17. 17.
    Oweini H, Otrock ZK, Mahfouz RA, Bazarbachi A (2011) Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet 283(1):133–134CrossRefPubMedGoogle Scholar
  18. 18.
    Abrusezze E, Trawinska MM, Perrotti AP, De Fabritiis P (2014) Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis 6(1):e2014028CrossRefGoogle Scholar
  19. 19.
    Pye SM, Cortes J, Ault P, Hatfied A, Kantarjian H, Pilot R, Rosti G, Apperly J (2008) The effects of Imatinib on pregnancy outcome. Blood 111:5505–5508CrossRefPubMedGoogle Scholar
  20. 20.
    Laferla JJ (1986) Spontaneous abortion. Clin Obstet Gynaecol 13:105–114PubMedGoogle Scholar
  21. 21.
    Soriano P (1997) The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 124:2691–2700PubMedGoogle Scholar
  22. 22.
    Bleyl SB, Moshrefi A, Shaw GM, Saijoh Y, Schoenwolf GC, Pennacchio LA, Slavotinek AM (2007) Candidate genes for congenital diaphragmatic hernia from animal models: sequencing of FOG2 and PDGFR alpha reveals rare variants in diaphragmatic hernia patients. Eur J Hum Genet 15:950–958CrossRefPubMedGoogle Scholar
  23. 23.
    Sun T, Jayatilake D, Afink GB, Ataliotis P, Nistér M, Richardson WD, Smith HK (2000) A human YAC transgene rescues craniofacial and neural tube development in PDGFR alpha knockout mice and uncovers a role for PDGFR alpha in prenatal lung growth. Development 127:4519–4529PubMedGoogle Scholar
  24. 24.
    Bayraktar S, Morency B, Escalon MP (2010) Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester. BMJ Case Reports Online PublicationGoogle Scholar
  25. 25.
    Conchon M, Sanabani SS, Serpa M, Novaes MM, Nardinelli L, Ferreira PB, Dorliac-Lacer PE, Bendit I (2010) Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol 2010:136252CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Kroll T, Ames MB, Pruett JA, Fenske TS (2010) Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib. Leuk Lymphoma 51(9):1751–1753CrossRefPubMedGoogle Scholar
  27. 27.
    Dine G, Levert M, Rehn Y, Ali AN, Brahimi S, Gaillard B, Bocq I, Fumagalli G (2013) Two successful successive pregnancies in a woman with CML treated with dasatinib and temporary peg-interferon. J US-China Med Sci 10(5–6):128–133Google Scholar
  28. 28.
    Berveiller P, Andreoli A, Mir O, Anselem O, Delezoide AL, Sauvageon H, Chapuis N, Tsatsaris V (2012) A dramatic fetal outcome following transplacental transfer of dasatinib. Anti-Cancer Drugs 23(7):754–757CrossRefPubMedGoogle Scholar
  29. 29.
    Conchon M, Sanabani SS, Bendit I (2009) Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol 42(2)Google Scholar
  30. 30.
    Etienne G, Milpied B, Réa D, Rigal-Huguet F, Tulliez M, Nicolini FE (2010) French Intergroup of CML (Fi-LMC group). Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group). Bull Cancer 97(8):997–1009PubMedGoogle Scholar
  31. 31.
    Goh HG, Kim YJ, Kim DW, Kim HJ, Kim SH, Jang SE, Lee J, Kim D, Kim WS, Park SH, Kweon IY (2009) Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukaemia: implications for intermittent imatinib therapy. Leuk Lymphoma 50(6):944–951CrossRefPubMedGoogle Scholar
  32. 32.
    Kuwabara A, Babb A, Ibrahim A, Milojkovic D, Apperley J, Bua M, Reid A, Foroni L, Rezvani K, Goldman J, Marin D (2010) Poor outcome after reintroduction of imatinib in patients with CML who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 116(6):1014–1016CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Baer MR, Ozer H, Foon KA (1992) Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. Br J Haematol 81(2):167–169CrossRefPubMedGoogle Scholar
  34. 34.
    Mubarak AA, Kakil IR, Awidi A, Al-Homsi U, Fawzi Z, Kelta M, Al-Hassan A (2002) Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-a in 1st trimester: report of 3 cases and review of the literature. Am J Hematol 69:115–118CrossRefPubMedGoogle Scholar
  35. 35.
    Hiratsuka M, Minakami H, Koshizuka S, Sato I (2000) Administration of interferon-a during pregnancy: effect on fetus. J Perinat Med 28:372–376CrossRefPubMedGoogle Scholar
  36. 36.
    Vantroyen B, Vanstraelen D (2002) Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha 2a and no treatment. A comprehensive analysis of the literature. Acta Hematol 107:158–169CrossRefGoogle Scholar
  37. 37.
    Regierer AC, Schulz CO, Kuehnhardt D, Flath B, Possinger K (2006) Interferon a—therapy for chronic myeloid leukemia during pregnancy. Am J Hematol 81:149–156CrossRefPubMedGoogle Scholar
  38. 38.
    Al Bahar S, Pandita R, Nath SV (2004) Pregnancy in chronic myeloid leukemia patients treated with alpha interferon. Int J Gynecol Obstet 85:281–282CrossRefGoogle Scholar
  39. 39.
    Kuroiwa M, Gondo H, Ashida K, Kamimura T, Miyamoto T, Niho Y, Tsukimori K, Nakano H, Ohga S (1998) Interferon alpha therapy for chronic myeloid leukemia during pregnancy. Am J Hematol 59:101–102CrossRefPubMedGoogle Scholar
  40. 40.
    Thauvin Robinet C, Maingueneau C, Robert E, Elefant E, Guy H, Caillot D, Casasnovas RO, Douvier S, Nivelon-Chevallier A (2001) Exposure to hydroxyurea during pregnancy: a case series. Leukemia 15:1309–1311CrossRefPubMedGoogle Scholar
  41. 41.
    Fadilah SA, Ahmad-Zailani H, Soon-Keng C, Norlaila M (2002) Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea. Leukemia 16:1202–1203CrossRefPubMedGoogle Scholar
  42. 42.
    Russel MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ (2007) Imatinib mesylate and metabolite concentration in maternal blood, umbelical cord blood, placenta and breast milk. J Perinatol 27:241–243CrossRefGoogle Scholar
  43. 43.
    Ali R, Ozkalemkas F, Kimya Y, Koksal N, Ozkocaman V, Gulten T, Yorulmaz H, Tunali A (2009) Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 280(2):169–175, 2008CrossRefPubMedGoogle Scholar
  44. 44.
    (2006) Bristol-Myers Squibb Canada. HYDREA® product monograph. Montreal, QuebecGoogle Scholar
  45. 45.
    Kumar AR, Hale TW, Mock RE (2000) Transfer of interferon alfa into human breast milk. J Hum Lact 16(3):226–228CrossRefPubMedGoogle Scholar
  46. 46.
    Lichtman MLJ (2001) 6th ed. Vol. 1047. New York, NY: McGraw-Hill. Acute myelogenous leukemia. Williams HematologyGoogle Scholar
  47. 47.
    Sheehy WT (1958) An evaluation of the effect of pregnancy on chronic granulocytic leukaemia. Am J Obstet Gynecol 75:788PubMedGoogle Scholar
  48. 48.
    Ali R, Ozkalemkaş F, Ozkocaman V, Ozçelik T, Ozan U, Kimya Y, Tunali A (2004) Successful pregnancy and delivery in patient with CML and management of CML with leukapheresis during pregnancy. Jpn J Clin Oncol 34:215–217CrossRefPubMedGoogle Scholar
  49. 49.
    Klaasen R, de-Jong P, Wijermans PW (2007) Successful management of chronic myeloid leukemia with leucapheresis during a twin pregnancy. Neth J Med 65:147–149PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Renuka Palani
    • 1
  • Dragana Milojkovic
    • 1
  • Jane F. Apperley
    • 1
  1. 1.Department of Haematology, Imperial College LondonHammersmith HospitalLondonUK

Personalised recommendations